NASDAQ:RDNT

RadNet Stock Forecast, Price & News

$34.53
-0.32 (-0.92 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.24
$35.25
50-Day Range
$25.65
$36.00
52-Week Range
$13.49
$36.64
Volume133,587 shs
Average Volume220,894 shs
Market Capitalization$1.82 billion
P/E Ratio172.65
Dividend YieldN/A
Beta1.69
30 days | 90 days | 365 days | Advanced Chart
Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.


RadNet logo

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

679th out of 2,210 stocks

Medical Laboratories Industry

14th out of 41 stocks

Analyst Opinion: 1.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











RadNet (NASDAQ:RDNT) Frequently Asked Questions

Is RadNet a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RadNet stock.
View analyst ratings for RadNet
or view top-rated stocks.

What stocks does MarketBeat like better than RadNet?

Wall Street analysts have given RadNet a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but RadNet wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting RadNet?

RadNet saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,390,000 shares, an increase of 23.0% from the June 30th total of 1,130,000 shares. Based on an average trading volume of 250,600 shares, the days-to-cover ratio is currently 5.5 days. Currently, 3.1% of the company's shares are sold short.
View RadNet's Short Interest
.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for RadNet
.

How can I listen to RadNet's earnings call?

RadNet will be holding an earnings conference call on Monday, August 9th at 10:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "3277272".

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) posted its quarterly earnings results on Monday, May, 10th. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.08. The medical research company had revenue of $315.30 million for the quarter, compared to analyst estimates of $283.07 million. RadNet had a trailing twelve-month return on equity of 4.80% and a net margin of 0.99%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.33) EPS.
View RadNet's earnings history
.

How has RadNet's stock price been impacted by COVID-19 (Coronavirus)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDNT stock has increased by 100.5% and is now trading at $34.53.
View which stocks have been most impacted by COVID-19
.

What guidance has RadNet issued on next quarter's earnings?

RadNet updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $1.28 billion-1.33 billion, compared to the consensus revenue estimate of $1.27 billion.

What price target have analysts set for RDNT?

2 equities research analysts have issued twelve-month price objectives for RadNet's shares. Their forecasts range from $26.00 to $40.00. On average, they anticipate RadNet's stock price to reach $33.00 in the next twelve months. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for RadNet
or view top-rated stocks among Wall Street analysts.

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres & CEO (Age 75, Pay $2.84M)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 50, Pay $650.84k)
  • Mr. Mital Patel, Exec. VP of Financial Planning & Analysis and Chief Admin. Officer (Age 35, Pay $613.86k)
  • Mr. Norman R. Hames, Pres & COO of Western Operations (Age 65, Pay $732.8k)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 60, Pay $751.62k)
  • Mr. Ranjan Jayanathan, Exec. VP, Chief Information Officer & GM of eRAD - Radiology Information Technology Division (Age 65)
  • Ms. Laura Foster BSRT, MPH, J.D., Sr. VP of Compliance & Regulatory Affairs
  • Mr. David Jeffrey Katz, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57)
  • Ms. Ruth Louisa Wilson, Sr. VP of HR & Director (Age 57)
  • Mr. Michael M. Murdock, Exec. VP & Chief Devel. Officer (Age 66)

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet CEO Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among RadNet's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), The Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.06%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, John V Crues, Lawrence L Levitt, Mark Stolper, Michael L Md Sherman, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends for RadNet
.

Which major investors are buying RadNet stock?

RDNT stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought RadNet stock in the last two years include B Kaplan Survivor's Tru Karen, and Lawrence L Levitt.
View insider buying and selling activity for RadNet
or or view top insider-buying stocks.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $34.53.

How much money does RadNet make?

RadNet has a market capitalization of $1.82 billion and generates $1.07 billion in revenue each year. The medical research company earns $-14,840,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does RadNet have?

RadNet employs 8,327 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

Where are RadNet's headquarters?

RadNet is headquartered at 1510 COTNER AVE, LOS ANGELES CA, 90025.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at (310) 478-7808 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.